Ozempic and other GLP-1 receptor agonists have swept the world for obesity and type 2 diabetes. Their extended value is reducing inflammation and improving clinical outcomes in heart disease by 20% or more. Kidney diseases along with promising but less consistent evidence in liver diseases, while research in autoimmune diseases and dementia remains preliminary.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
These cookies are needed for adding comments on this website.
Google reCAPTCHA helps protect websites from spam and abuse by verifying user interactions through challenges.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com (opens in a new window)
